SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Corixa [CRXA] - cancer vaccines -- Ignore unavailable to you. Want to Upgrade?


To: Andreas Helke who wrote (5)5/18/1998 9:22:00 PM
From: scaram(o)uche  Read Replies (1) | Respond to of 222
 
Andreas:

CRXA and "the" vaccine take top spot at Medscape today......

Online Coverage from the
American Society of Clinical Oncology
May 16-19, 1998
c Medscape, Inc.
Antitumor Peptide Vaccine Induces Specific T-Cell
Immunity to HER-2/neu

Speaker: Mary Disis, MD, University of Washington

Reporter: Philip Schulman, MD, North Shore University Hospital, Manhasset, NY
Reviewer: Eric K. Rowinsky, MD, Cancer Therapy and Research Center, San Antonio, Tex

Introduction

A peptide-based vaccine elicited specific T-cell responses against both HER-2
peptides and the HER-2 protein (snip)

Miljenko Zuanic had predicted that CRXA was going to pop on this news, and I just started watching it over the weekend. Congrats!

Rick